Scholarlink

<p>Brazil and India are megadiverse countries with rich traditions of medicinal plant use. Ayurveda, one of India’s traditional medicine systems, is officially recognized within Brazilian public health policies, offering an opportunity for cross-cultural exchange and integration. This study compared medicinal plants and therapeutic uses documented in the Ayurvedic Pharmacopoeia of India (Volumes I–X) and Brazilian official sources (the Brazilian Pharmacopoeia and its complementary documents, the Herbal Formulary and <i>Memento de Fitoterápicos</i>). Only herbal drug monographs were analyzed. Therapeutic indications were categorized using the International Classification of Diseases 11th Revision (ICD-11). Of the 396 plant species documented in the Ayurvedic pharmacopoeia and 158 in Brazilian sources, only 30 species overlapped. Among these, just 15 had comparable therapeutic indications across ICD-11. Our analysis revealed low similarity between the therapeutic indications listed in the Indian and Brazilian pharmacopoeias. These differences highlight the influence of epistemological and therapeutic frameworks, cultural practices, and preparation methods. Despite low overlap, 144 Ayurvedic species are found in the&#xa0;Brazilian flora, indicating potential for bioprospecting, innovation, and expansion of the country’s therapeutic arsenal. Integrating validated traditional knowledge can support evidence-based health policies and strengthen the development of phytotherapeutic products in Brazil.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Comparison of Ayurvedic and Brazilian Pharmacopoeias: Therapeutic Potential and Public Health Implications

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月18日

查看全文
  • Bárbara Esteves das Neves,
  • Asmita Wele,
  • Nina Claudia Barboza da Silva

摘要

Brazil and India are megadiverse countries with rich traditions of medicinal plant use. Ayurveda, one of India’s traditional medicine systems, is officially recognized within Brazilian public health policies, offering an opportunity for cross-cultural exchange and integration. This study compared medicinal plants and therapeutic uses documented in the Ayurvedic Pharmacopoeia of India (Volumes I–X) and Brazilian official sources (the Brazilian Pharmacopoeia and its complementary documents, the Herbal Formulary and Memento de Fitoterápicos). Only herbal drug monographs were analyzed. Therapeutic indications were categorized using the International Classification of Diseases 11th Revision (ICD-11). Of the 396 plant species documented in the Ayurvedic pharmacopoeia and 158 in Brazilian sources, only 30 species overlapped. Among these, just 15 had comparable therapeutic indications across ICD-11. Our analysis revealed low similarity between the therapeutic indications listed in the Indian and Brazilian pharmacopoeias. These differences highlight the influence of epistemological and therapeutic frameworks, cultural practices, and preparation methods. Despite low overlap, 144 Ayurvedic species are found in the Brazilian flora, indicating potential for bioprospecting, innovation, and expansion of the country’s therapeutic arsenal. Integrating validated traditional knowledge can support evidence-based health policies and strengthen the development of phytotherapeutic products in Brazil.